Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study.

Mischoulon D, De Jong MF, Vitolo OV, Cusin C, Dording CM, Yeung AS, Durham K, Parkin SR, Fava M, Dougherty DD.

J Psychiatr Res. 2015 Nov;70:98-105. doi: 10.1016/j.jpsychires.2015.08.016. Epub 2015 Aug 29.

PMID:
26424428
2.

A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women.

Dording CM, Schettler PJ, Dalton ED, Parkin SR, Walker RS, Fehling KB, Fava M, Mischoulon D.

Evid Based Complement Alternat Med. 2015;2015:949036. doi: 10.1155/2015/949036. Epub 2015 Apr 14.

3.

A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M.

J Clin Psychiatry. 2014 Apr;75(4):370-6. doi: 10.4088/JCP.13m08591.

4.

The effect of sildenafil on quality of life.

Dording CM, LaRocca RA, Hails KA, Vitolo OV, Wisniewski SR, Balasubramani GK, Trivedi M, Fava M, Mischoulon D.

Ann Clin Psychiatry. 2013 Feb;25(1):3-10.

PMID:
23376864
5.

Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.

Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M.

CNS Spectr. 2012 Jun;17(2):76-86. doi: 10.1017/S1092852912000430.

6.

Comparison of academic and nonacademic sites in multi-center clinical trials.

Dording CM, Dalton ED, Pencina MJ, Fava M, Mischoulon D.

J Clin Psychopharmacol. 2012 Feb;32(1):65-8. doi: 10.1097/JCP.0b013e31823f3b47.

PMID:
22198440
7.

Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire.

Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D.

J Clin Psychiatry. 2011 Aug;72(8):1152-4. doi: 10.4088/JCP.11ac07225. No abstract available.

8.

Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.

Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM.

Prim Care Companion CNS Disord. 2011;13(1). pii: PCC.10m00994. doi: 10.4088/PCC.10m00994gre.

9.

SAMe and sexual functioning.

Dording CM, Mischoulon D, Shyu I, Alpert JE, Papakostas GI.

Eur Psychiatry. 2012 Aug;27(6):451-4. doi: 10.1016/j.eurpsy.2011.01.003. Epub 2011 Mar 12.

PMID:
21398094
10.

Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome.

Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI.

CNS Spectr. 2010 Aug;15(8):515-21.

PMID:
20703198
11.

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.

Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M.

J Clin Psychiatry. 2009 Dec;70(12):1636-44. doi: 10.4088/JCP.08m04603. Epub 2009 Aug 25.

12.

The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.

Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D.

Nord J Psychiatry. 2009;63(5):420-5. doi: 10.1080/08039480903015396.

PMID:
19521922
13.

A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.

Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D.

CNS Neurosci Ther. 2008 Fall;14(3):182-91. doi: 10.1111/j.1755-5949.2008.00052.x.

PMID:
18801111
14.

A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.

Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, Papakostas GI, Dording CM, Sonawalla SB, Nierenberg AA, Alpert JE, Fava M.

Eur Neuropsychopharmacol. 2008 Sep;18(9):639-45. doi: 10.1016/j.euroneuro.2008.04.011. Epub 2008 Jun 6.

PMID:
18539007
15.

The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.

Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M.

Ann Clin Psychiatry. 2002 Sep;14(3):143-7.

PMID:
12585563
16.

An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.

Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R, Fava M.

J Clin Psychiatry. 2002 Dec;63(12):1164-70.

PMID:
12523877
17.

Antidepressant augmentation and combinations.

Dording CM.

Psychiatr Clin North Am. 2000 Dec;23(4):743-55. Review.

PMID:
11147245

Supplemental Content

Loading ...
Support Center